90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
PHASE1
This phase I trial is to find out the best dose, possible benefits and/or s...
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
PHASE2
Graft-versus-host disease (GVHD) is a major factor affecting the efficacy a...
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
PHASE4
To investigate whether the addition of recombinant humanized anti-CD25 mono...
Status
Recruiting
Location
Beijing Children's Hospital Capital Medical University
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
PHASE1
Background:
Adult T-cell leukemia (ATL) is a rare blood cancer. Researcher...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
PHASE2
This phase II trials studies the effects of yttrium-90 labeled anti-CD25 mo...
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
PHASE2
This study will evaluate a new immunosupressive therapy, Daclizumab, and co...